TransMedics Group, Inc. (NASDAQ:TMDX) Director Edward M. Basile Sells 6,750 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now owns 732 shares in the company, valued at $61,158.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

TransMedics Group Stock Up 0.6 %

Shares of NASDAQ TMDX opened at $85.98 on Friday. The business has a 50-day simple moving average of $132.03 and a two-hundred day simple moving average of $139.20. The company has a market cap of $2.89 billion, a P/E ratio of 91.47 and a beta of 2.08. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 52 week low of $55.29 and a 52 week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.12) earnings per share. Research analysts anticipate that TransMedics Group, Inc. will post 1.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TransMedics Group

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of TransMedics Group by 1.3% during the first quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock valued at $139,680,000 after acquiring an additional 23,979 shares in the last quarter. Driehaus Capital Management LLC lifted its position in TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after purchasing an additional 202,867 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of TransMedics Group by 5.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock worth $94,061,000 after purchasing an additional 30,092 shares in the last quarter. Vaughan Nelson Investment Management L.P. lifted its position in shares of TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after acquiring an additional 64,360 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of TransMedics Group by 8.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 297,324 shares of the company’s stock worth $21,985,000 after acquiring an additional 22,223 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on TMDX shares. Oppenheimer reduced their price target on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, October 29th. Piper Sandler reissued an “overweight” rating and set a $180.00 target price on shares of TransMedics Group in a report on Tuesday, October 29th. Canaccord Genuity Group dropped their price target on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. Robert W. Baird cut their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, October 29th. Finally, JPMorgan Chase & Co. decreased their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, TransMedics Group has a consensus rating of “Buy” and a consensus target price of $144.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.